Twenty-five adult epileptic patients who had shown a satisfactory clinical response to add-on Vigabatrin (VGB) under placebo-controlled conditions continued on long-term treatment for up to 47 months (median 22 months). The initially favourable therapeutic response was generally maintained throughout the observation period with an oveall good clinical tolerability. No evidence of neurotoxicity was detected by multimodal evoked potentials monitoring.
|Title of host publication||Bollettino - Lega Italiana contro l'Epilessia|
|Number of pages||2|
|Publication status||Published - 1988|
ASJC Scopus subject areas
- Clinical Neurology